Phase I study of GRN1005 in recurrent malignant glioma

Clinical Cancer Research

Volumn 19, Issue 6, 2013, Pages 1567-1576

  Drappatz, Jan ^a,b,d,e   Brenner, Andrew ^f   Wong, Eric T ^c,d   Eichler, April ^b,d   Schiff, David ^h   Groves, Morris D ^g   Mikkelsen, Tom ⁱ   Rosenfeld, Steve ^j   Sarantopoulos, John ^f   Meyers, Christina A ^g   Fielding, Robert M ^k   Elian, Kelly ^l   Wang, Xiaolin ^m   Lawrence, Betty ^l   Shing, Mona ^m   Kelsey, Stephen ^m   Castaigne, Jean Paul ^l   Wen, Patrick Y ^a,b,d  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^f UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^g UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^h UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

ⁱ HENRY FORD HOSPITAL   (United States)

^j NEUROLOGICAL INSTITUTE   (United States)

^k Biologistic Services Boulder   (United States)

^l ANGIOCHEM INC   (Canada)

^m GERON CORPORATION   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

GRN 1005; PACLITAXEL; PACLITAXEL DERIVATIVE; UNCLASSIFIED DRUG;

ADULT; AGED; ANEMIA; ANTIBODY PRODUCTION; ARTICLE; ATAXIA; BACTERIAL MENINGITIS; BACTERIAL PNEUMONIA; CANDIDIASIS; CENTRAL NERVOUS SYSTEM DISEASE; CONSTIPATION; CONVULSION; DIARRHEA; DIZZINESS; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG TUMOR LEVEL; DRUG WITHDRAWAL; DYSPEPSIA; FATIGUE; FEMALE; GLIOBLASTOMA; HEADACHE; HEMIPARESIS; HUMAN; HUMAN TISSUE; INFUSION RELATED REACTION; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MAXIMUM TOLERATED DOSE; MUCOSA INFLAMMATION; MULTICENTER STUDY; NAUSEA; NEUROTOXICITY; NEUTROPENIA; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; SOMNOLENCE; STOMATITIS; THROMBOCYTOPENIA; THRUSH; URINARY TRACT INFECTION; VOMITING;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BLOOD-BRAIN BARRIER; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG TOXICITY; FEMALE; GLIOMA; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PACLITAXEL; PEPTIDES;

EID: 84875125427     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-2481     Document Type: Article

References (47)

1. Wen PY, Kesari S. Malignant gliomas in adults. N Engl J Med 2008; 359:492-507.
2. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987-96.
3. Wen PY, Brandes AA. Treatment of recurrent high-grade gliomas. Curr Opin Neurol 2009;22:657-64.
4. Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 2009;27:4733-40.
5. Kreisl TN, KimL, Moore K, Duic P, Royce C, Stroud I, et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 2009; 27:740-5.
6. Quant EC, Norden AD, Drappatz J, Muzikansky A, Doherty L, Lafrankie D, et al. Role of a second chemotherapy in recurrent malignant glioma patients who progress on bevacizumab. Neuro Oncol 2009; 11:550-5.
7. Wick W, Puduvalli VK, Chamberlain MC, van den Bent MJ, Carpentier AF, Cher LM, et al. Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma. J Clin Oncol 2010;28:1168-74.
8. Demeule M, Regina A, Jodoin J, Laplante A, Dagenais C, Berthelet F, et al. Drug transport to the brain: key roles for the efflux pump Pglycoprotein in the blood-brain barrier. Vascul Pharmacol 2002; 38:339-48.
9. Kemper EM, Boogerd W, Thuis I, Beijnen JH, van Tellingen O. Modulation of the blood-brain barrier in oncology: therapeutic opportunities for the treatment of brain tumours? Cancer Treat Rev 2004;30: 415-23.
10. Decleves X, Amiel A, Delattre JY, Scherrmann JM. Role of ABC transporters in the chemoresistance of human gliomas. Curr Cancer Drug Targets 2006;6:433-45.
11. Potschka H. Targeting the brain-surmounting or bypassing the bloodbrain barrier. Handb Exp Pharmacol 2010;411-31.
12. Pardridge WM. Drug targeting to the brain. Pharm Res 2007;24: 1733-44.
13. Lillis AP, Van Duyn LB, Murphy-Ullrich JE, Strickland DK. LDL receptor- related protein 1: unique tissue-specific functions revealed by selective gene knockout studies. Physiol Rev 2008;88:887-918.
14. Fillebeen C, Descamps L, Dehouck MP, Fenart L, Benaissa M, Spik G, et al. Receptor-mediated transcytosis of lactoferrin through the bloodbrain barrier. J Biol Chem 1999;274:7011-7.
15. Demeule M, Poirier J, Jodoin J, Bertrand Y, Desrosiers RR, Dagenais C, et al. High transcytosis of melanotransferrin (P97) across the bloodbrain barrier. J Neurochem 2002;83:924-33.
16. Pan W, Kastin AJ, Zankel TC, van Kerkhof P, Terasaki T, Bu G. Efficient transfer of receptor-associated protein (RAP) across the blood-brain barrier. J Cell Sci 2004;117:5071-8.
17. Benchenane K, Berezowski V, Ali C, Fernandez-Monreal M, Lopez- Atalaya JP, Brillault J, et al. Tissue-type plasminogen activator crosses the intact blood-brain barrier by low-density lipoprotein receptorrelated protein-mediated transcytosis. Circulation 2005;111:2241-9.
18. Demeule M, Regina A, Che C, Poirier J, Nguyen T, Gabathuler R, et al. Identification and design of peptides as a new drug delivery system for the brain. J Pharmacol Exp Ther 2008;324:1064-72.
19. Kounnas MZ, Moir RD, Rebeck GW, Bush AI, Argraves WS, Tanzi RE, et al. LDL receptor-related protein, a multifunctional ApoE receptor, binds secreted beta-amyloid precursor protein and mediates its degradation. Cell 1995;82:331-40.
20. Shibata M, Yamada S, Kumar SR, Calero M, Bading J, Frangione B, et al. Clearance of Alzheimer's amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. J Clin Invest 2000;106:1489-99.
21. Tooyama I, Kawamata T, Akiyama H, Kimura H, Moestrup SK, Gliemann J, et al. Subcellular localization of the low density lipoprotein receptor-related protein (alpha 2-macroglobulin receptor) in human brain. Brain Res 1995;691:235-8.
22. Wolf BB, Lopes MB, VandenBerg SR, Gonias SL. Characterization and immunohistochemical localization of alpha 2-macroglobulin receptor (low-density lipoprotein receptor-related protein) in human brain. Am J Pathol 1992;141:37-42.
23. Maletinska L, Blakely EA, Bjornstad KA, Deen DF, Knoff LJ, Forte TM. Human glioblastoma cell lines: levels of low-density lipoprotein receptor and low-density lipoprotein receptor-related protein. Cancer Res 2000;60:2300-3.
24. Dedieu S, Langlois B. LRP-1: a new modulator of cytoskeleton dynamics and adhesive complex turnover in cancer cells. Cell Adh Migr 2008;2:77-80.
25. Demeule M, Currie JC, Bertrand Y, Che C, Nguyen T, Regina A, et al. Involvement of the low-density lipoprotein receptor-related protein in the transcytosis of the brain delivery vector angiopep-2. J Neurochem 2008;106:1534-44.
26. Thomas FC, Taskar K, Rudraraju V, Goda S, Thorsheim HR, Gaasch JA, et al. Uptake of ANG1005, a novel paclitaxel derivative, through the blood-brain barrier into brain and experimental brain metastases of breast cancer. Pharm Res 2009;26:2486-94.
27. Langlois B, Perrot G, Schneider C, Henriet P, Emonard H, Martiny L, et al. LRP-1 promotes cancer cell invasion by supporting ERK and inhibiting JNK signaling pathways. PLoS One 2010;5:e11584.
28. Crown J, O'Leary M. The taxanes: an update. Lancet 2000;355: 1176-8.
29. Cahan MA, Walter KA, Colvin OM, Brem H. Cytotoxicity of taxol in vitro against human and rat malignant brain tumors. Cancer Chemother Pharmacol 1994;33:441-4.
30. Glantz MJ, Chamberlain MC, Chang SM, Prados MD, Cole BF. The role of paclitaxel in the treatment of primary and metastatic brain tumors. Semin Radiat Oncol 1999;9:27-33.
31. Prados MD, Schold SC, Spence AM, Berger MS, McAllister LD, Mehta MP, et al. Phase II study of paclitaxel in patients with recurrent malignant glioma. J Clin Oncol 1996;14:2316-21.
32. Fruehauf JP, Brem H, Brem S, Sloan A, Barger G, Huang W, et al. In vitro drug response and molecular markers associated with drug resistance in malignant gliomas. Clin Cancer Res 2006;12:4523-32.
33. Urquhart BL, Kim RB. Blood-brain barrier transporters and response to CNS-active drugs. Eur J Clin Pharmacol 2009;65:1063-70.
34. Heimans JJ, Vermorken JB, Wolbers JG, Eeltink CM, Meijer OW, Taphoorn MJ, et al. Paclitaxel (Taxol) concentrations in brain tumor tissue. Ann Oncol 1994;5:951-3.
35. Fellner S, Bauer B, Miller DS, Schaffrik M, Fankhanel M, Spruss T, et al. Transport of paclitaxel (Taxol) across the blood-brain barrier in vitro and in vivo. J Clin Invest 2002;110:1309-18.
36. Fine RL, Chen J, Balmaceda C, Bruce JN, Huang M, Desai M, et al. Randomized study of paclitaxel and tamoxifen deposition into human brain tumors: implications for the treatment of metastatic brain tumors. Clin Cancer Res 2006;12:5770-6.
37. Regina A, Demeule M, Che C, Lavallee I, Poirier J, Gabathuler R, et al. Antitumour activity of ANG1005, a conjugate between paclitaxel and the new brain delivery vector Angiopep-2. Br J Pharmacol 2008;155: 185-97.
38. Yamamoto M, Ikeda K, Ohshima K, Tsugu H, Kimura H, Tomonaga M. Expression and cellular localization of low-density lipoprotein receptor-related protein/alpha 2-macroglobulin receptor in human glioblastoma in vivo. Brain Tumor Pathol 1998;15:23-30.
39. Omura GA. Phase 1 dose-finding trials and fibonacci. Clin Cancer Res 2006;12:321.
40. Meyers CA, Brown PD. Role and relevance of neurocognitive assessment in clinical trials of patients with CNS tumors. J Clin Oncol 2006;24:1305-9.
41. Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 1990;8:1277-80.
42. Aronen HJ, Gazit IE, Louis DN, Buchbinder BR, Pardo FS, Weisskoff RM, et al. Cerebral blood volume maps of gliomas: comparison with tumor grade and histologic findings. Radiology 1994; 191:41-51.
43. Tyler JL, Diksic M, Villemure JG, Evans AC, Meyer E, Yamamoto YL, et al. Metabolic and hemodynamic evaluation of gliomas using positron emission tomography. J Nucl Med 1987;28: 1123-33.
44. Sadeghi N, D'Haene N, Decaestecker C, Levivier M, Metens T, Maris C, et al. Apparent diffusion coefficient and cerebral blood volume in brain gliomas: relation to tumor cell density and tumor microvessel density based on stereotactic biopsies. Am J Neuroradiol 2008;29:476-82.
45. Liu XR, Wu KC, Huang Y, Sun JB, Ke XY, Wang JC, et al. In vitro and in vivo studies on plasma-to-blood ratio of paclitaxel in human, rabbit and rat blood fractions. Biol Pharm Bull 2008;31:1215-20.
46. Sparreboom A, van Tellingen O, Nooijen WJ, Beijnen JH. Tissue distribution, metabolismand excretion of paclitaxel in mice. Anticancer Drugs 1996;7:78-86.
47. Kurzrock R, Gabrail N, Chandhasin C, Moulder S, Smith C, Brenner A, et al. Safety, pharmacokinetics, and activity of GRN1005, a novel conjugate of angiopep-2, a peptide facilitating brain penetration, and paclitaxel, in patients with advanced solid tumors. Mol Cancer Ther 2012;11:308-16.